Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-06669571
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PF-06669571 is a novel, orally administered small molecule that acts as a partial agonist of the dopamine D1 receptor. It was developed by Pfizer for the treatment of Parkinson's disease and cognition disorders. The drug was designed to address unmet medical needs in Parkinson's disease by targeting dopaminergic pathways through selective activation of the D1 receptor, which is implicated in motor control and cognitive function. Clinical studies demonstrated that multiple daily doses were safe and well tolerated but did not meet pre-specified efficacy endpoints for significant improvement in motor symptoms or cognition. Development has been discontinued for both indications.
- Other names
- razpipadon
02
Targets
DRD1 (Dopamine D1 Receptor)DRD5 (Dopamine D5 Receptor)
Beyond the preview
Go deeper on PF-06669571.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-06669571.